Latest Conference Articles

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.

Despite an excellent safety and tolerability profile and proven efficacy in treating atrial fibrillation, PFA failed to prove superiority to RA.

Alnylam Pharmaceuticals debuts phase 2 KARDIA-3 data at ESC 2025 and advances zilebesiran into a phase 3 outcomes trial.

Olezarsen shows promise in significantly lowering triglyceride levels in patients with hypertriglyceridemia.

The investigative aldosterone synthase inhibitor reduced seated systolic blood pressure in patients with uncontrolled or resistant hypertension compared to placebo.

Aficamten shows significant benefits over metoprolol in treating symptomatic obstructive HCM, potentially changing first-line therapy approaches.

Aficamten displayed superior improvements in peak oxygen uptake and hemodynamics compared to the most commonly used beta-blocker for symptomatically obstructive HCM.

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

Avacincaptad pegol, pegcetacoplan, and aflibercept 8mg do not increase risk of ocular hypertension and glaucoma, despite having higher volumes.

Results from a recent trial indicated continuously decreasing risks of all forms of retinal vascular occlusion and retinal vein occlusion for 5 years after treatment.

Both trials indicated lasting visual improvements in patients treated with Ixo-vec who had previously received anti-VEGF injections.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

An interim report from the ongoing trial shows few adverse events resulting from 60 weeks of treatment with the combined AAV vector/dual-transgene cassette.

In this summary of coverage at the DERM 2025 conference, a list of notable stories highlighting acne management strategies is highlighted.

The new, bioerodible intravitreal implant, which periodically releases the tyrose kinase inhibitor vorolanib, may be capable of reducing treatment burden for at least 6 months.

In this list of the top 5 posters featured at the DERM 2025 conference, a variety of recent data are spotlighted in alopecia areata, atopic dermatitis, and other disease states.

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

This summary covers a variety of notable DERM 2025 conference news highlights, specifically in the area of alopecia areata.

This list highlights a variety of notable DERM 2025 conference news coverage, specifically in the field of atopic dermatitis.

The larger dose exhibited better gains in best-corrected visual acuity with fewer injections during the study period.

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

The PAISLEY CLE trial findings highlight deucravacitinib’s efficacy among patients with cutaneous lupus, including those with concurrent SLE.

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.